Literature DB >> 16125160

Blood oxidative stress markers in Gaucher disease patients.

Fernanda M Roversi1, Luciano C Galdieri, Bruno H C Grego, Fernanda G Souza, Cecília Micheletti, Ana Maria Martins, Vânia D'Almeida.   

Abstract

BACKGROUND: Gaucher disease (GD) is the most common glycosphingolipidosis resulting in accumulation of glucoceramide. The most effective treatment for this disease is enzyme replacement therapy (ERT) which involves recombinant enzyme infusion. Enzymatic deficiency in GD patients may induce a cascade of events culminating in secondary effects such as the production of reactive oxygen species (ROS). We investigated the relationship between ROS and GD by analyzing blood oxidative stress markers in GD patients submitted to ERT at different stages during the treatment.
METHODS: Blood were collected before and just after enzyme infusion. Red blood cell catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD) and total glutathione (tGSH), and plasma thiobarbituric acid reactive substances (TBARS) were assayed by spectrophotometry. Homocysteine concentrations and related polymorphisms were also studied. Control individuals matched for sex and age were also analyzed.
RESULTS: Concentrations of homocysteine and TBARS, and GPx enzyme activity were not different in ERT-treated GD patients. CAT activity was higher while SOD was lower in patients compared to controls. No variations in any of these parameters were found before and just after ERT. Regarding tGSH, a significant increase was observed in GD patients after infusion. Genotypic frequencies studied did not differ from controls or other Brazilian samples.
CONCLUSION: ERT-treated GD patients show an improvement in antioxidant capacity, which is further increased just after recombinant enzyme infusion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16125160     DOI: 10.1016/j.cca.2005.07.022

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  9 in total

Review 1.  Common and uncommon pathogenic cascades in lysosomal storage diseases.

Authors:  Einat B Vitner; Frances M Platt; Anthony H Futerman
Journal:  J Biol Chem       Date:  2010-04-29       Impact factor: 5.157

Review 2.  Combination therapies for lysosomal storage disease: is the whole greater than the sum of its parts?

Authors:  Jacqueline A Hawkins-Salsbury; Adarsh S Reddy; Mark S Sands
Journal:  Hum Mol Genet       Date:  2011-03-19       Impact factor: 6.150

3.  N-Acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases.

Authors:  Mary J Holmay; Melissa Terpstra; Lisa D Coles; Usha Mishra; Matthew Ahlskog; Gülin Öz; James C Cloyd; Paul J Tuite
Journal:  Clin Neuropharmacol       Date:  2013 Jul-Aug       Impact factor: 1.592

4.  Type of diet modulates the metabolic response to sleep deprivation in rats.

Authors:  Paulo Jf Martins; Leandro Fernandes; Allan C de Oliveira; Sergio Tufik; Vânia D'Almeida
Journal:  Nutr Metab (Lond)       Date:  2011-12-12       Impact factor: 4.169

5.  Ceria-Zirconia nanoparticles reduce intracellular globotriaosylceramide accumulation and attenuate kidney injury by enhancing the autophagy flux in cellular and animal models of Fabry disease.

Authors:  Jong Hun An; Sang-Eun Hong; Seong-Lan Yu; Jaeku Kang; Chang Gyo Park; Hoi Young Lee; Sung-Ki Lee; Dong Chul Lee; Hwan-Woo Park; Won-Min Hwang; Sung-Ro Yun; Yohan Park; Moon Hyang Park; Kuk Ro Yoon; Se-Hee Yoon
Journal:  J Nanobiotechnology       Date:  2022-03-09       Impact factor: 10.435

6.  Biological Variation in Peripheral Inflammation and Oxidative Stress Biomarkers in Individuals with Gaucher Disease.

Authors:  Siddhee A Sahasrabudhe; Marcia R Terluk; Kyle D Rudser; James C Cloyd; Reena V Kartha
Journal:  Int J Mol Sci       Date:  2022-08-16       Impact factor: 6.208

7.  Evaluation of oxidative stress markers and cardiovascular risk factors in Fabry Disease patients.

Authors:  Karen B Müller; Luciano C Galdieri; Vanessa G Pereira; Ana M Martins; Vânia D'Almeida
Journal:  Genet Mol Biol       Date:  2012-05-17       Impact factor: 1.771

8.  Probing the in vitro cytotoxicity of the veterinary drug oxytetracycline.

Authors:  Zhenxing Chi; Rutao Liu; Hong You; Shanshan Ma; Hao Cui; Qiang Zhang
Journal:  PLoS One       Date:  2014-07-14       Impact factor: 3.240

9.  Oxidative stress parameters of Gaucher disease type I patients.

Authors:  Alexandre Silva Mello; Cristina da Silva Garcia; Fernanda de Souza Machado; Niara da Silva Medeiros; Mariane Farias Wohlenberg; Jéssica Pereira Marinho; Caroline Dani; Cláudia Funchal; Janice Carneiro Coelho
Journal:  Mol Genet Metab Rep       Date:  2015-05-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.